Pfizer's US $43 million stake in nimbus helps Nash therapy research and development

Source: Biovalley March 19, 2015 nimbus therapeutics, a well-known preclinical research company, said that the company had completed a round B financing with a total amount of US $43 million The name of Pfizer, a Chinese pharmaceutical giant in the financing, stands out, indicating that another biopharmaceutical giant will support nimbus's development In addition to Pfizer ventures, Sr one, Lily ventures and other well-known investment companies active in the field of biomedicine of GlaxoSmithKline are all involved, and even billionaire Bill Gates is involved Nimbus therapeutics used its unique technology to provide computer simulation drug screening services for major biomedical companies Under the leadership of new CEO don Nicholson, nimbus therapeutics will gradually enter the field of clinical research For this reason, nimbus therapeutics specifically replaced the "discovery" in the company name with "therapeutics" To announce the transfer of the company's future development focus After the financing, nimbus will start the clinical research of its first drug The drug is an acetyl CoA carboxylase (CAA) inhibitor, mainly used in the treatment of nonalcoholic steatohepatitis (NASH) Don Nicholson claims it is the first CAA inhibitor for NASH so far With the improvement of people's living standards, there are hundreds of millions of patients with fatty liver disease in the world It can be said that Nash has become one of the important diseases threatening human health As a result, Nash is considered to be the next gold mine for biomedical developers Nimbus plans to use this round of investment to push the drug into clinical research, and it is expected that the second phase of clinical research of the drug will start in the first half of 2016 In addition, the company also disclosed that it has signed two cooperation projects with shire and Monsanto respectively, but did not disclose specific details.